DalsnaFinance

Syndax Pharmaceuticals Inc $SNDX

Health Care

Russell 2000 New York
Create a scorecard
$13.57
+0.42 (+3.19%)
As of Oct 22, 2026, 9:33 PM EDT · cached
Price history
Loading chart…

Syndax Pharmaceuticals Inc (SNDX) is trading up at $13.57 (+3.19%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

IPO: March 3, 2016 · $12.00 offering · NASDAQ · View IPO details →

Syndax Pharmaceuticals Inc revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$172.4M−$73.2M−$318.8MFY2016 revenue: $1.22MFY2016 net income: −$44.5M · Net margin −3645.2%'16FY2017 revenue: $2.11MFY2017 net income: −$60.8M · Net margin −2884.3%'17FY2018 revenue: $1.52MFY2018 net income: −$74.0M · Net margin −4875.5%'18FY2019 revenue: $1.52MFY2019 net income: −$56.0M · Net margin −3694.6%'19FY2020 revenue: $1.52MFY2020 net income: −$73.2M · Net margin −4822.5%'20FY2021 revenue: $139.7MFY2021 net income: $24.9M · Net margin 17.8%'21FY2022 revenue: $0FY2022 net income: −$149.3M'22FY2023 revenue: $0FY2023 net income: −$209.4M'23FY2024 revenue: $23.7MFY2024 net income: −$318.8M · Net margin −1346.1%'24FY2025 revenue: $172.4MFY2025 net income: −$285.4M · Net margin −165.6%'25−92.5%−50%0%50%FY2016 net margin: −3645.2% (off the scale, which stops at −92.5%)FY2017 net margin: −2884.3% (off the scale, which stops at −92.5%)FY2018 net margin: −4875.5% (off the scale, which stops at −92.5%)FY2019 net margin: −3694.6% (off the scale, which stops at −92.5%)FY2020 net margin: −4822.5% (off the scale, which stops at −92.5%)FY2021 net margin: 17.8%FY2024 net margin: −1346.1% (off the scale, which stops at −92.5%)FY2025 net margin: −165.6% (off the scale, which stops at −92.5%)
Syndax Pharmaceuticals Inc annual financial statements
FY2016Dec 2016FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$1.22M$2.11M$1.52M$1.52M$1.52M$139.7M$0$0$23.7M$172.4M
Growth (year over year)+94.6%+72.8%−28.0%0.0%0.0%+9109.6%−100.0%——+627.8%
Operating income−$43.8M−$62.0M−$75.9M−$57.5M−$71.4M$26.2M−$151.8M−$230.0M−$339.7M−$273.1M
Operating margin−3587.4%−2939.0%−5001.7%−3792.9%−4708.2%18.8%——−1434.4%−158.4%
Net income−$44.5M−$60.8M−$74.0M−$56.0M−$73.2M$24.9M−$149.3M−$209.4M−$318.8M−$285.4M
Net margin−3645.2%−2884.3%−4875.5%−3694.6%−4822.5%17.8%——−1346.1%−165.6%
EPS (diluted)−$3.22−$2.90−$2.92−$1.84−$1.87$0.46−$2.46−$2.98−$3.72−$3.29
Balance sheet
Cash and equivalents$23.8M$35.2M$33.8M$24.6M$115.2M$222.0M$74.4M$295.4M$154.1M$134.9M
Total assets$109.0M$137.2M$83.9M$63.5M$300.6M$449.7M$497.2M$612.9M$724.8M$529.7M
Total liabilities$24.9M$32.9M$30.9M$31.9M$48.4M$41.3M$29.8M$58.7M$436.7M$465.1M
Shareholders' equity$84.1M$104.3M$53.0M$31.6M$252.2M$408.4M$467.4M$554.2M$288.1M$64.6M
Cash flow
Operating cash flow−$35.2M−$47.4M−$68.5M−$50.6M−$71.3M$29.1M−$133.7M−$160.6M−$274.9M−$323.0M
Capital expenditure$261.0K$84.0K$187.0K—$0$129.0K$0$0$0$187.0K
Free cash flow−$35.4M−$47.5M−$68.7M—−$71.3M$29.0M−$133.7M−$160.6M−$274.9M−$323.2M

From Syndax Pharmaceuticals Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About Syndax Pharmaceuticals Inc

Headquarters
New York, New York From SEC filings, Oct 2026

Recent News (4)

More Health Care stocks

Browse all companies →